Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

Elicio Therapeutics announced that its CEO Robert Connelly and Chief Scientific Officer Pete DeMuth will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The clinical-stage biotech company is developing next-generation immunotherapies for KRAS-driven cancers, with its lead program ELI-002 7P targeting the most common KRAS mutations found in approximately 25% of solid tumors.

08/31/2026, 8:00 AM • GlobeNewswire

Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering

Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotech company, announced a registered direct offering of 4.38 million shares expected to raise approximately $15 million gross proceeds. The company plans to use the funds to support Phase 1 clinical development of ELI-002 7P in metastatic pancreatic cancer, pipeline advancement, and general corporate purposes. The offering is expected to close on or about July 6, 2026.

07/02/2026, 12:25 AM • GlobeNewswire

Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes

Elicio Therapeutics (ELTX), a clinical-stage biotech company developing immunotherapies for KRAS-driven cancers, was added to the Russell 2000 and Russell 3000 indexes as of June 26, 2026. The company is advancing its lead candidate ELI-002 7P, an off-the-shelf cancer immunotherapy targeting common KRAS mutations. However, the Phase 2 AMPLIFY-7P trial did not meet its primary endpoint of disease-free survival, prompting Elicio to refine its Phase 3 development strategy and initiate a Phase 1 study in metastatic pancreatic cancer.

06/29/2026, 8:00 AM • GlobeNewswire

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics announced that its Phase 2 AMPLIFY-7P study of ELI-002 7P did not meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer. However, post-hoc analyses showed promising results in the R0 resected patient subgroup (84% of enrolled patients) with a hazard ratio of 0.65 (p=0.048). Strong correlations between mutant KRAS-specific T cell responses and improved outcomes supported the drug's biological activity. The company plans to refine its Phase 3 strategy focusing on R0 resected patients with extended dosing, pending financing.

06/15/2026, 7:00 AM • GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics granted 30,300 inducement stock options to a new employee on February 17, 2026, at an exercise price of $8.59 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly thereafter, subject to continued employment.

02/18/2026, 8:00 AM • GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics granted 22,400 inducement stock options to two new employees on January 15, 2026, at an exercise price of $7.81 per share. The options vest over four years with 25% vesting on the first anniversary and the remainder vesting ratably monthly thereafter.

01/16/2026, 8:00 AM • GlobeNewswire

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

Elicio Therapeutics appointed Marc J. Wolfgang as Chief Technology Officer, bringing over 30 years of biopharmaceutical leadership experience to strengthen the company's late-stage and commercial readiness for its immunotherapy pipeline.

11/19/2025, 8:00 AM • GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

Elicio Therapeutics announced successful results for its ELI-002 off-the-shelf cancer vaccine, which induced mKRAS-specific T cell responses in 99% of evaluable patients. The vaccine targets common KRAS mutations in solid tumors and showed promising survival outcomes in pancreatic and colorectal cancer patients.

09/18/2025, 8:00 AM • GlobeNewswire

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

Elicio Therapeutics published extended follow-up data for its ELI-002 cancer vaccine, showing promising results in treating minimal residual disease-positive patients with pancreatic and colorectal cancers, with significant reductions in death and relapse risks.

08/12/2025, 8:00 AM • GlobeNewswire